https://dompe.com/content/dompefarmaceutici.htmlhttps://dompe.com/content/dompefarmaceutici/global.html2025-12-02https://dompe.com/2026-01-13https://dompe.com/about-us/2026-03-10https://dompe.com/about-us/who-we-are/2026-01-13https://dompe.com/about-us/who-we-are/history/2026-01-13https://dompe.com/about-us/who-we-are/management-team/2026-01-12https://dompe.com/about-us/who-we-are/management-team/leadership/sergio-dompe/2025-12-03https://dompe.com/about-us/who-we-are/management-team/leadership/nathalie-dompe/2025-12-02https://dompe.com/about-us/who-we-are/management-team/innovation/shannon-k--sullivan/2025-12-02https://dompe.com/about-us/who-we-are/management-team/innovation/marcello-allegretti/2025-12-02https://dompe.com/about-us/who-we-are/management-team/innovation/ahmed-enayetallah/2025-12-03https://dompe.com/about-us/who-we-are/management-team/business-and-operation/marc-kubasak/2025-12-02https://dompe.com/about-us/who-we-are/management-team/business-and-operation/davide-polimeni/2025-12-02https://dompe.com/about-us/who-we-are/management-team/business-and-operation/stefano-arena/2025-12-02https://dompe.com/about-us/who-we-are/management-team/business-and-operation/gianluca-rossetti/2026-02-06https://dompe.com/about-us/who-we-are/management-team/enabling-functions/giuseppe-andreano/2025-12-02https://dompe.com/about-us/who-we-are/management-team/enabling-functions/andrea-astolfi/2025-12-02https://dompe.com/about-us/who-we-are/management-team/enabling-functions/monica-fantino/2025-12-02https://dompe.com/about-us/who-we-are/management-team/enabling-functions/guido-romeo/2025-12-02https://dompe.com/about-us/who-we-are/management-team/enabling-functions/daniele-rizzo/2025-12-02https://dompe.com/about-us/who-we-are/management-team/enabling-functions/sheila-folayan/2025-12-02https://dompe.com/about-us/who-we-are/management-team/enabling-functions/marco-radice/2025-12-02https://dompe.com/about-us/who-we-are/environment-quality-and-safety/2026-03-10https://dompe.com/about-us/who-we-are/ethics-and-compliance/2026-03-12https://dompe.com/about-us/where-we-are/2026-03-12https://dompe.com/about-us/where-we-are/manufacturing-biotech/2026-03-10https://dompe.com/about-us/where-we-are/manufacturing-pharma/2026-03-12https://dompe.com/about-us/where-we-are/offices/2026-02-04https://dompe.com/science/2025-12-02https://dompe.com/science/nerve-growth-factor/2026-03-10https://dompe.com/science/pipeline/2026-04-02https://dompe.com/science/disease-focus/2025-12-02https://dompe.com/science/disease-focus/neurotrophic-keratitis/2026-03-10https://dompe.com/science/disease-focus/non-arteritic-anterior-ischemic-optic-neuropathy/2026-03-10https://dompe.com/science/disease-focus/atopic-keratoconjunctivitis/2026-04-02https://dompe.com/science/disease-focus/cerebral-palsy/2026-03-27https://dompe.com/science/exscalate/2026-03-10https://dompe.com/medicines/2025-12-02https://dompe.com/medicines/primary-and-specialty-care/2025-12-02https://dompe.com/medicines/primary-and-specialty-care/pain-and-inflammation/2026-03-10https://dompe.com/medicines/primary-and-specialty-care/cold-and-cough/2026-03-10https://dompe.com/medicines/primary-and-specialty-care/gastro/2026-03-10https://dompe.com/medicines/primary-and-specialty-care/cardiovascular/2026-03-10https://dompe.com/medicines/primary-and-specialty-care/eye-skin-and-oral-care/2026-03-10https://dompe.com/medicines/primary-and-specialty-care/prevention/2026-03-10https://dompe.com/medicines/ophthalmics/2026-03-10https://dompe.com/medicines/managed-access-programs/2026-03-10https://dompe.com/media/2025-12-02https://dompe.com/media/news/2025-12-09https://dompe.com/media/news/press-release/from-the-eye-to-the-brain-world-s-top-scientists-gather-in-rome-to-discuss-future-of-neurotrophins-in-eye-and-brain-research/2025-12-10https://dompe.com/media/news/press-release/dompe-s-program-in-naion-selected-for-landmark-fda-commissioner-s-national-priority-voucher-program/2025-12-03https://dompe.com/media/news/press-release/dompe-farmaceutici-appoints-shannon-k-sullivan-as-chief-commercial-officer-biotech/2025-12-09https://dompe.com/media/news/press-release/eni-e-dompe-insieme-per-attivita-di-ricerca-nell-ambito-salute/2025-12-03https://dompe.com/media/news/press-release/dompe-farmaceutici-and-farmamondo-group-extend-their-distribution-partnership-for-oxervate/2025-12-03https://dompe.com/media/news/press-release/dompe-foundation-doubles-its-funding-for-rita-levi-montalcini-fellowships-in-neuroscience-and-neurobiology/2025-12-03https://dompe.com/media/news/press-release/new-data-reveal-role-of-sars-cov-2-spike-protein-in-covid-19-associated-coagulopathy/2025-12-03https://dompe.com/media/news/press-release/dompe-first-user-of-the-leonardo-supercomputer-the-first-technology-transfer-agreement-is-to-accelerate-life-sciences-with-the-exscalate-platform/2025-12-03https://dompe.com/media/news/press-release/new-published-data-point-to-spike-protein-interactions-with-estrogen-receptors-as-a-cause-for-coagulopathy-in-covid-19-patients-signaling-sex-effects-and-a-path-to-improved-vaccines/2025-12-03https://dompe.com/media/news/press-release/searching-for-the-light-when-darkness-falls-the-challenge-of-rare-eye-diseases-becomes-a-short-film-with-the-fightforlight-campaign/2025-12-03https://dompe.com/media/news/press-release/cenegermin-eye-drops-receive-european-union-approval-the-first-biotechnological-drug-resulting-from-dompe-research-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-is-made-in-italy/2025-12-03https://dompe.com/media/news/press-release/dompe-receives-positive-chmp-opinion-in-europe-for-oxervater/2025-12-03https://dompe.com/media/news/press-release/a-focus-on-well-being-and-ongoing-prevention-dompes-commitment-to-athletes/2025-12-03https://dompe.com/media/news/press-release/dompe-announces-the-untimely-death-of-its-chief-executive-officer-eugenio-aringhieri/2025-12-03https://dompe.com/media/news/press-release/dompe-to-present-phase-ii-clinical-data-for-ladarixin-in-new-onset-type-1-diabetes-t1d-at-the-american-diabetes-associations-scientific-sessions/2025-12-03https://dompe.com/media/news/press-release/dompe-receives-industry-innovation-award-from-the-national-organization-for-rare-disorders-for-the-development-of-oxervatetm-eye-drops-cenegermin-bkbj-for-neurotrophic-keratitis/2025-12-03https://dompe.com/media/news/press-release/exscalate4cov-performed-in-italy-the-most-complex-supercomputing-experiment-to-identify-new-therapies-against-sars-cov2-virus/2025-12-02https://dompe.com/media/news/press-release/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2/2025-12-03https://dompe.com/media/news/press-release/exscalate-epidemics-exscalate-is-the-worlds-most-powerful-supercomputing-platform/2025-12-03https://dompe.com/media/news/press-release/ligate-new-european-backed-effort-against-pandemics-kicks-off-with-59-mln-euro/2025-12-03https://dompe.com/media/news/press-release/italian-researchers-abroad-and-a-startup-from-rome-win-the-first-call-for-ideas-by-dompe-the-selected-projects-concern-ophthalmology-and-the-wellness-area/2025-12-03https://dompe.com/media/news/press-release/3-clinical-trial-of-dompes-reparixin-for-the-treatment-of-severe-patients-with-covid-19-pneumonia/2025-12-02https://dompe.com/media/news/press-release/molmed-and-dompe-signed-strategic-commercialization-and-supply-agreements-for-zalmoxisr-in-europe/2025-12-03https://dompe.com/media/news/press-release/exscalate4cov-eus-supercomputing-and-life-science-champions-gear-up-to-fight-coronavirus-pandemic/2025-12-03https://dompe.com/media/news/press-release/dompe-announces-zalmoxisr-product-launch-in-germany/2025-12-03https://dompe.com/media/news/press-release/dompe-launches-first-biotechnological-therapy-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-in-germany/2025-12-03https://dompe.com/media/news/press-release/dompe-completed-investments-cycle-for-expansion-of-the-production-research-and-development-site-in-laquila/2025-12-03https://dompe.com/media/news/press-release/exscalate4cov-italian-medicines-agency-aifa-authorizes-raloxifene-clinical-trial-for-paucisymptomatic-covid-19-patients-treated-at-home-and-in-medical-facilities/2025-12-03https://dompe.com/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-ladarixin-an-oral-investigational-cxcr1-2-inhibitor-in-new-onset-type-1-diabetes-t1d/2025-12-03https://dompe.com/media/news/press-release/dompe-announces-results-of-phase-2-study-evaluating-the-efficacy-and-safety-of-reparixin-in-patients-with-severe-covid-19-pneumonia/2025-12-03https://dompe.com/media/news/press-release/dompe-and-the-farmamondo-group-exsclusive-agreement-to-distribute-oxervatetm-in-russia-and-other-cis-countries/2025-12-03https://dompe.com/media/news/press-release/project-neon-is-underway-in-lombardy-the-public-and-private-sector-have-come-together-to-meet-the-needs-of-those-suffering-from-diseases-of-the-nervous-system-and-tumours-with-a-high-need-for-treatment/2025-12-03https://dompe.com/media/news/press-release/dompe-receives-fda-approval-cenegermin-eye-drops-first-in-class-recombinant-human-nerve-growth-factor-with-potential-to-completely-heal-rare-neurotrophic-keratitis/2025-12-03https://dompe.com/media/news/press-release/friliverr-sport-is-an-official-partner-of-the-federazione-italiana-triathlon/2025-12-03https://dompe.com/media/news/press-release/european-and-south-korean-agreement-signed-on-joint-development-of-a-covid-19-treatment-using-raloxifene/2025-12-03https://dompe.com/media/news/press-release/dompe-substipharm-agreement-for-the-sale-of-6-brands/2025-12-03https://dompe.com/media/news/press-release/covid-19-brazilian-health-regulatory-agency-anvisa-authorizes-dompes-repavid-19-a-phase-2-clinical-trial-for-treatment-of-severe-patients/2025-12-03https://dompe.com/media/news/press-release/connectivity-specialisation-and-network-these-are-the-things-that-italians-want-from-the-pharmacy-of-the-future/2025-12-03https://dompe.com/media/news/press-release/dompe-further-elevates-commitment-to-ophthalmics-with-industry-leading-hires/2025-12-03https://dompe.com/media/news/press-release/the-galien-foundation-debuts-2019-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories/2025-12-03https://dompe.com/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2025-12-03https://dompe.com/media/news/press-release/dompe-farmaceutici-spa-announces-strategic-investment-and-collaboration-with-engitix-positioned-around-use-of-dompes-exscalate-drug-discovery-platform/2025-12-02https://dompe.com/media/news/press-release/leonardo-and-dompe-launch-the-first-national-digital-health-security-infrastructure-with-cloud-architecture/2025-12-03https://dompe.com/media/news/press-release/exscalate4cov-supercomputing-platform-wins-3-million-euro-eu-funding-to-hunt-for-new-drugs-against-coronavirus-pandemic/2025-12-03https://dompe.com/media/news/press-release/two-clinical-studies-to-treat-mild-to-moderate-covid-19-at-home-reveal-value-of-exscalate-dompes-ai-platform-for-drug-design/2025-12-03https://dompe.com/media/news/press-release/dompe-announces-activation-of-u-s-clinical-trial-sites-for-phase-3-study-of-reparixin-an-oral-investigational-cxcr1-cxcr2-inhibitor-in-hospitalized-patients-with-severe-covid-19-pneumonia/2025-12-09https://dompe.com/media/news/press-release/dompe-doses-first-patients-in-europe-and-us-in-phase-3-study-of-isocyclosporin-for-atopic-keratoconjunctivitis/2025-12-16https://dompe.com/media/news/press-release/dompe-announces-first-patient-enrolled-in-new-study-of-intranasal-ngf-in-cerebral-palsy/2026-03-30https://dompe.com/media/press/2026-02-06https://dompe.com/careers/2025-12-02https://dompe.com/careers/people-and-culture/2026-03-12https://dompe.com/careers/join-us/2026-03-10https://dompe.com/holdings/2026-03-10https://dompe.com/pharmacovigilance-and-vigilance/2026-03-10https://dompe.com/contact/2026-01-12https://dompe.com/privacy-policy/2025-12-02https://dompe.com/terms-of-service/2026-03-10https://dompe.com/cookie-policy/2025-12-02https://dompe.com/supplier-customer-information/2025-12-02https://dompe.com/accessibility/2025-12-02https://dompe.com/quality-complaint/2025-12-10https://dompe.com/medical-information/2025-12-10https://dompe.com/privacy-notice-product-quality-complaints/2025-12-02https://dompe.com/personal-data-notice-pharmacovigilance/2025-12-02https://dompe.com/personal-data-notice-pharmacovigilance-albanian-territory/2025-12-02https://dompe.com/404/2025-12-02https://dompe.com/search/2025-12-02https://dompe.com/whistleblowing/2025-12-02https://dompe.com/managed-access-programs-privacy-policy/2025-12-02https://dompe.com/personal-data-notice-pharmacovigilance-switzerland-territory/2026-02-09https://dompe.com/content/dompefarmaceutici/it.html2025-12-02https://dompe.com/it/2026-01-13https://dompe.com/it/about-us/2026-03-10https://dompe.com/it/about-us/chi-siamo/2026-01-13https://dompe.com/it/about-us/chi-siamo/storia/2026-01-13https://dompe.com/it/about-us/chi-siamo/management-team/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/leadership/sergio-dompe/2025-12-03https://dompe.com/it/about-us/chi-siamo/management-team/leadership/nathalie-dompe/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/innovation/shannon-k--sullivan/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/innovation/marcello-allegretti/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/innovation/ahmed-enayetallah/2025-12-03https://dompe.com/it/about-us/chi-siamo/management-team/business-and-operation/marc-kubasak/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/business-and-operation/davide-polimeni/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/business-and-operation/stefano-arena/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/business-and-operation/gianluca-rossetti/2026-02-06https://dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/giuseppe-andreano/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/andrea-astolfi/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/monica-fantino/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/guido-romeo/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/daniele-rizzo/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/sheila-folayan/2025-12-02https://dompe.com/it/about-us/chi-siamo/management-team/enabling-functions/marco-radice/2025-12-02https://dompe.com/it/about-us/chi-siamo/ambiente-qualita-e-sicurezza/2026-03-10https://dompe.com/it/about-us/chi-siamo/etica-e-trasparenza/2026-03-10https://dompe.com/it/about-us/chi-siamo/tax-compliance/2025-12-02https://dompe.com/it/about-us/dove-siamo/2026-03-10https://dompe.com/it/about-us/dove-siamo/produzione-biotech/2026-03-10https://dompe.com/it/about-us/dove-siamo/produzione-pharma/2026-03-10https://dompe.com/it/about-us/dove-siamo/uffici/2026-02-04https://dompe.com/it/science/2025-12-02https://dompe.com/it/science/nerve-growth-factor/2026-03-10https://dompe.com/it/science/pipeline/2026-04-02https://dompe.com/it/science/disease-focus/2025-12-02https://dompe.com/it/science/disease-focus/cheratite-neurotrofica/2026-03-10https://dompe.com/it/science/disease-focus/neuropatia-ottica-ischemica-anteriore-non-arteritica/2026-03-10https://dompe.com/it/science/disease-focus/cheratocongiuntivite-atopica/2026-04-02https://dompe.com/it/science/disease-focus/paralisi-cerebrale-infantile/2026-03-27https://dompe.com/it/science/exscalate/2026-03-10https://dompe.com/it/science/progetti-finanziati/2026-03-10https://dompe.com/it/medicines/2025-12-02https://dompe.com/it/medicines/oftalmologia/2026-03-10https://dompe.com/it/medicines/primary-and-specialty-care/2025-12-02https://dompe.com/it/medicines/primary-and-specialty-care/infiammazione-e-dolore/2026-03-10https://dompe.com/it/medicines/primary-and-specialty-care/tosse-e-raffreddore/2026-03-10https://dompe.com/it/medicines/primary-and-specialty-care/gastro/2026-03-10https://dompe.com/it/medicines/primary-and-specialty-care/cardiovascolare/2026-03-10https://dompe.com/it/medicines/primary-and-specialty-care/eye-skin-and-oral-care/2026-03-10https://dompe.com/it/medicines/primary-and-specialty-care/prevenzione/2026-03-10https://dompe.com/it/medicines/ipertensione-arteriosa-polmonare/2026-03-10https://dompe.com/it/media/2025-12-02https://dompe.com/it/media/news/2025-12-02https://dompe.com/it/media/news/press-release/industria-del-talento-il-progetto-di-dompe-e-un-ponte-tra-studenti-e-industria-farmaceutica/2025-12-04https://dompe.com/it/media/news/press-release/from-the-eye-to-the-brain/2025-12-04https://dompe.com/it/media/news/press-release/dompe-farmaceutici-nomina-shannon-k-sullivan-come-chief-commercial-officer-biotech/2025-12-04https://dompe.com/it/media/news/press-release/il-programma-di-ricerca-di-dompe-farmaceutici-per-la-naion-e-stato-selezionato-per-l-iniziativa-landmark-fda-il-commissioner-s-national-priority-voucher-program/2025-12-04https://dompe.com/it/media/news/press-release/eni-e-dompe-insieme-per-attivita-di-ricerca-nell-ambito-salute/2025-12-04https://dompe.com/it/media/news/press-release/univaq-e-dompe-insieme-per-la-formazione-dei-talenti-nell-industria-delle-life-sciences/2025-12-04https://dompe.com/it/media/news/press-release/dompe-farmaceutici-il-nuovo-posizionamento-globale-parte-da-ricerca-e-digitale-ed-e-firmato-edelman/2025-12-04https://dompe.com/it/media/news/press-release/dompe-foundation-doubles-its-funding-for-rita-levi-montalcini-fellowships-in-neuroscience-and-neurobiology/2025-12-04https://dompe.com/it/media/news/press-release/covid-19-indicazioni-per-i-vaccini-di-nuova-generazione-da-studio-sul-ruolo-della-proteina-spike-di-sars-cov-2-nelle-coagulopatie/2025-12-03https://dompe.com/it/media/news/press-release/progetto-di-supercomputing-exscalate4cov-raloxifene-farmaco-candidato-per-contrastare-il-virus-sars-cov-2/2025-12-04https://dompe.com/it/media/news/press-release/ligate-new-european-backed-effort-against-pandemics-kicks-off-with-5-9-mln/2025-12-04https://dompe.com/it/media/news/press-release/the-galien-foundation-debuts-2019-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories/2025-12-04https://dompe.com/it/media/news/press-release/ricercatori-italiani-allestero-e-una-startup-romana-si-aggiudicano-la-prima-call-for-ideas-di-dompe-i-progetti-selezionati-riguardano-loftalmologia-e-larea-benessere/2025-12-04https://dompe.com/it/media/news/press-release/tra-like-ed-e-commerce-quali-modelli-per-la-farmacia-di-domani/2025-12-04https://dompe.com/it/media/news/press-release/molmed-e-dompe-stipulano-un-accordo-strategico-per-la-commercializzazione-e-la-fornitura-di-zalmoxis-in-europa/2025-12-04https://dompe.com/it/media/news/press-release/premi-di-laurea-2018-dompe-farmaceutici-e-comitato-leonardo-premiano-la-migliore-tesi-sugli-effetti-degli-amminoacidi-ramificati-sul-metabolismo-umano/2025-12-04https://dompe.com/it/media/news/press-release/nuove-terapie-e-meno-costi-per-la-sanita-con-i-farmaci-gia-approvati-parte-il-progetto-europeo-remedi4all/2025-12-04https://dompe.com/it/media/news/press-release/linnovazione-diventa-realta-al-via-a-milano-frilivertherace-la-prima-competizione-nazionale-di-triathlon-indoor/2025-12-04https://dompe.com/it/media/news/press-release/la-ricerca-della-luce-quando-scende-loscurita-la-sfida-alle-malattie-rare-degli-occhi-diventa-un-cortometraggio-con-la-campagna-fightforlight/2025-12-04https://dompe.com/it/media/news/press-release/leonardo-e-dompe-nasce-la-prima-infrastruttura-nazionale-di-sicurezza-sanitaria-digitale-con-architettura-cloud/2025-12-04https://dompe.com/it/media/news/press-release/nota-stampa-dompe-farmaceutici-dissociazione-da-messaggio-diffuso-via-social-media-relativo-ad-utilizzo-cebion/2025-12-04https://dompe.com/it/media/news/press-release/la-collaborazione-trasforma-la-ricerca-in-business/2025-12-04https://dompe.com/it/media/news/press-release/il-consorzio-exscalate4cov-progetto-di-riferimento-in-europa-per-contrastare-il-coronavirus-con-il-supercalcolo/2025-12-04https://dompe.com/it/media/news/press-release/dompe-farmaceutici-anche-la-food-and-drug-administration-approva-cenegermin-gocce-oculari-per-il-trattamento-della-cheratite-neurotrofica-frutto-della-ricerca-dompe/2025-12-03https://dompe.com/it/media/news/press-release/exscalate4cov-il-supercalcolo-e-le-eccellenze-delle-life-sciences-europee-in-campo-contro-il-coronavirus/2025-12-04https://dompe.com/it/media/news/press-release/exscalate4cov-eseguito-in-italia-lesperimento-di-supercalcolo-piu-complesso-mai-realizzato-al-mondo-per-identificare-nuove-terapie-contro-il-virus-sars-cov2/2025-12-04https://dompe.com/it/media/news/press-release/dompe-riceve-opinione-positiva-del-chmp-in-europa-per-oxervate/2025-12-04https://dompe.com/it/media/news/press-release/dompe-substipharm-agreement-for-the-sale-of-6-brands/2025-12-04https://dompe.com/it/media/news/press-release/lagenzia-brasiliana-del-farmaco-anvisa-autorizza-dompe-alla-sperimentazione-clinica-in-fase-2-di-reparixin-su-pazienti-covid-19-gravi/2025-12-04https://dompe.com/it/media/news/press-release/dompe-completato-ciclo-di-investimenti-per-lampliamento-del-sito-di-produzione-e-ricerca-e-sviluppo-dellaquila/2025-12-03https://dompe.com/it/media/news/press-release/connessione-specializzazione-e-network-ecco-cosa-chiedono-gli-italiani-alla-farmacia-del-futuro/2025-12-03https://dompe.com/it/media/news/press-release/dompe-farmaceutici-al-via-sidebyside4innovation-il-contest-volto-a-supportare-i-progetti-di-innovazione-in-oftalmologia-e-nutrizione/2025-12-03https://dompe.com/it/media/news/press-release/dompe-announces-results-of-phase-2-study-evaluating-the-efficacy-and-safety-of-reparixin-in-patients-with-severe-covid-19-pneumonia/2025-12-03https://dompe.com/it/media/news/press-release/dompe-farmaceutici-e-comitato-leonardo-premiano-la-migliore-tesi-sui-meccanismi-alla-base-dello-sviluppo-della-fatigue-in-pazienti-oncologici/2025-12-03https://dompe.com/it/media/news/press-release/exscalate-frutto-della-collaborazione-tra-dompe-farmaceutici-politecnico-di-milano-e-cineca-e-italiano-il-supercalcolo-intelligente-piu-potente-e-a-basso-costo-al-mondo-a-supporto-della-ricerca-di-terapie-in-caso-di-epidemie/2025-12-02https://dompe.com/it/media/news/press-release/cxcr2-inhibitor-in-hospitalized-patients-with-severe-covid-19-pneumonia/2025-12-03https://dompe.com/it/media/news/press-release/due-nuovi-studi-italia-usa-indicano-nelle-interazioni-della-proteina-spike-con-i-recettori-degli-estrogeni-la-causa-della-coagulopatia-nei-pazienti-covid-19-indicazioni-per-migliorare-la-prossima-generazione-di-vaccini-anti-covid/2025-12-02https://dompe.com/it/media/news/press-release/al-via-il-progetto-neon-pubblico-e-privato-si-alleano-in-lombardia-per-rispondere-ai-bisogni-di-chi-soffre-di-malattie-del-sistema-nervoso-e-tumori-ad-elevato-bisogno-di-cura/2025-12-03https://dompe.com/it/media/news/press-release/farmacisti-a-scuola-di-futuro-digitale-parte-da-napoli-liniziativa-itinerante-firmata-dompe/2025-12-04https://dompe.com/it/media/news/press-release/cenegermin-collirio-soluzione-riceve-lapprovazione-europea-e-made-in-italy-il-primo-farmaco-biotecnologico-frutto-della-ricerca-dompe-per-il-trattamento-della-cheratite-neurotrofica-moderata-o-grave/2025-12-03https://dompe.com/it/media/news/press-release/dompe-announces-zalmoxis-product-launch-in-germany/2025-12-03https://dompe.com/it/media/news/press-release/european-and-south-korean-agreement-signed-on-joint-development-of-a-covid-19-treatment-using-raloxifene/2025-12-04https://dompe.com/it/media/news/press-release/due-studi-clinici-per-il-trattamento-domiciliare-del-covid-19-da-lieve-a-moderato-confermano-il-valore-di-exscalate-la-piattaforma-ai-di-dompe-per-il-drug-design/2025-12-04https://dompe.com/it/media/news/press-release/exscalate4cov-via-libera-da-aifa-ad-avvio-studio-clinico-su-raloxifene-per-il-trattamento-di-pazienti-covid-paucisintomatici-ospedalizzati-o-a-domicilio/2025-12-04https://dompe.com/it/media/news/press-release/2-inhibitor-in-new-onset-type-1-diabetes-t1d/2025-12-02https://dompe.com/it/media/news/press-release/3-clinical-trial-of-reparixin-for-the-treatment-of-severe-patients-with-covid-19-pneumonia/2025-12-03https://dompe.com/it/media/news/press-release/dompe-investimenti-strategici-e-collaborazione-con-engitix-per-luso-di-exscalate-la-piattaforma-di-intelligenza-artificiale-per-la-drug-discovery/2025-12-04https://dompe.com/it/media/news/press-release/friliver-sport-e-partner-ufficiale-della-federazione-italiana-triathlon/2025-12-04https://dompe.com/it/media/news/press-release/dompe-launches-first-biotechnological-therapy-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-in-germany/2025-12-04https://dompe.com/it/media/news/press-release/dompe-primo-utente-del-supercomputer-leonardo-con-la-piattaforma-exscalate/2025-12-04https://dompe.com/it/media/news/press-release/attenzione-al-benessere-e-prevenzione-continua-limpegno-dompe-al-fianco-dello-sportivo/2025-12-03https://dompe.com/it/media/news/press-release/dompe-farmaceutici-continuiamo-ad-assumere-e-investire-per-mantenere-eccellenza-e-competitivita/2025-12-03https://dompe.com/it/media/news/press-release/dompe-farmaceutici-annuncia-la-prematura-scomparsa-dellad-eugenio-aringhieri/2025-12-03https://dompe.com/it/media/news/press-release/comunicazione-partecipazione-al-capitale-sociale-di-philogen-s-p-a/2025-12-03https://dompe.com/it/media/news/press-release/dompe-further-elevates-commitment-to-ophthalmics-with-industry-leading-hires/2025-12-04https://dompe.com/it/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2025-12-03https://dompe.com/it/media/news/press-release/dompe-and-the-farmamondo-group-exsclusive-agreement-to-distribute-oxervate-in-russia-and-other-cis-countries/2025-12-03https://dompe.com/it/media/news/press-release/dompe-receives-industry-innovation-award-from-the-national-organization-for-rare-disorders-for-the-development-of-oxervatetm-eye-drops-cenegermin-bkbj-for-neurotrophic-keratitis/2025-12-04https://dompe.com/it/media/news/press-release/dompe-avvia-la-somministrazione-ai-primi-pazienti-in-europa-e-stati-uniti-nello-studio-di-fase-3-con-isociclosporina-nella-cheratocongiuntivite-atopica/2025-12-16https://dompe.com/it/media/news/press-release/dompe-farmaceutici-arruolato-il-primo-paziente-nello-studio-per-il-trattamento-della-paralisi-cerebrale-infantile-con-somministrazione-intranasale-di-ngf/2026-03-30https://dompe.com/it/media/press/2026-02-06https://dompe.com/it/careers/2025-12-02https://dompe.com/it/careers/people-and-culture/2026-03-10https://dompe.com/it/careers/lavora-con-noi/2026-03-10https://dompe.com/it/holdings/2026-03-10https://dompe.com/it/farmacovigilanza-e-vigilanza/2026-03-10https://dompe.com/it/contatti/2026-03-10https://dompe.com/it/informativa-privacy/2025-12-02https://dompe.com/it/condizioni-di-utilizzo/2026-03-10https://dompe.com/it/informativa-cookie/2025-12-02https://dompe.com/it/informativa-clienti-e-fornitori/2025-12-02https://dompe.com/it/accessibilit%C3%A0/2026-03-10https://dompe.com/it/reclami-di-qualita/2026-03-10https://dompe.com/it/informazione-medica/2026-03-10https://dompe.com/it/informativa-privacy%20-reclami-sulla-qualit%C3%A0-di-prodotto/2025-12-02https://dompe.com/it/politica-sul-trattamento-dei-dati-relativi-alla-farmacovigilanza/2025-12-02https://dompe.com/it/404/2025-12-02https://dompe.com/it/search/2025-12-02https://dompe.com/it/whistleblowing/2025-12-02https://dompe.com/content/dompefarmaceutici/us.html2025-12-02https://dompe.com/us/2026-01-13https://dompe.com/us/about-us/2026-01-15https://dompe.com/us/about-us/who-we-are/2026-01-13https://dompe.com/us/about-us/who-we-are/history/2026-01-13https://dompe.com/us/about-us/who-we-are/management-team/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/leadership/sergio-dompe/2025-12-03https://dompe.com/us/about-us/who-we-are/management-team/leadership/nathalie-dompe/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/innovation/shannon-k--sullivan/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/innovation/marcello-allegretti/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/innovation/ahmed-enayetallah/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/business-and-operation/marc-kubasak/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/business-and-operation/davide-polimeni/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/business-and-operation/stefano-arena/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/business-and-operation/gianluca-rossetti/2026-02-06https://dompe.com/us/about-us/who-we-are/management-team/enabling-functions/giuseppe-andreano/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/enabling-functions/andrea-astolfi/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/enabling-functions/monica-fantino/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/enabling-functions/guido-romeo/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/enabling-functions/daniele-rizzo/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/enabling-functions/sheila-folayan/2025-12-02https://dompe.com/us/about-us/who-we-are/management-team/enabling-functions/marco-radice/2025-12-02https://dompe.com/us/about-us/who-we-are/environment-quality-and-safety/2026-03-10https://dompe.com/us/about-us/who-we-are/ethics-and-compliance/2026-03-10https://dompe.com/us/about-us/who-we-are/grants-and-donations/2026-03-10https://dompe.com/us/about-us/where-we-are/2026-03-12https://dompe.com/us/about-us/where-we-are/manufacturing-biotech/2026-03-10https://dompe.com/us/about-us/where-we-are/manufacturing-pharma/2026-03-10https://dompe.com/us/about-us/where-we-are/offices/2026-02-04https://dompe.com/us/science/2025-12-02https://dompe.com/us/science/nerve-growth-factor/2026-03-12https://dompe.com/us/science/pipeline/2026-04-02https://dompe.com/us/science/disease-focus/2025-12-02https://dompe.com/us/science/disease-focus/neurotrophic-keratitis/2026-03-10https://dompe.com/us/science/disease-focus/non-arteritic-anterior-ischemic-optic-neuropathy/2026-03-10https://dompe.com/us/science/disease-focus/atopic-keratoconjunctivitis/2026-04-02https://dompe.com/us/science/disease-focus/cerebral-palsy/2026-03-27https://dompe.com/us/science/exscalate/2026-03-10https://dompe.com/us/medicines/2025-12-02https://dompe.com/us/medicines/ophthalmics/2026-03-10https://dompe.com/us/media/2025-12-02https://dompe.com/us/media/news/2025-12-02https://dompe.com/us/media/news/press-release/dompe-farmaceutici-appoints-shannon-k-sullivan-as-chief-commercial-officer-biotech/2025-12-03https://dompe.com/us/media/news/press-release/dompe-s-program-in-naion-selected-for-landmark-fda-commissioner-s-national-priority-voucher-program/2025-12-03https://dompe.com/us/media/news/press-release/dompe-foundation-doubles-its-funding-for-rita-levi-montalcini-fellowships-in-neuroscience-and-neurobiology/2025-12-03https://dompe.com/us/media/news/press-release/new-data-reveal-role-of-sars-cov-2-spike-protein-in-covid-19-associated-coagulopathy/2025-12-03https://dompe.com/us/media/news/press-release/new-published-data-point-to-spike-protein-interactions-with-estrogen-receptors-as-a-cause-for-coagulopathy-in-covid-19-patients-signaling-sex-effects-and-a-path-to-improved-vaccines/2025-12-03https://dompe.com/us/media/news/press-release/searching-for-the-light-when-darkness-falls-the-challenge-of-rare-eye-diseases-becomes-a-short-film-with-the-fightforlight-campaign/2025-12-03https://dompe.com/us/media/news/press-release/cenegermin-eye-drops-receive-european-union-approval-the-first-biotechnological-drug-resulting-from-dompe-research-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-is-made-in-italy/2025-12-03https://dompe.com/us/media/news/press-release/dompe-receives-positive-chmp-opinion-in-europe-for-oxervater/2025-12-03https://dompe.com/us/media/news/press-release/a-focus-on-well-being-and-ongoing-prevention-dompes-commitment-to-athletes/2025-12-03https://dompe.com/us/media/news/press-release/dompe-announces-the-untimely-death-of-its-chief-executive-officer-eugenio-aringhieri/2025-12-03https://dompe.com/us/media/news/press-release/dompe-to-present-phase-ii-clinical-data-for-ladarixin-in-new-onset-type-1-diabetes-t1d-at-the-american-diabetes-associations-scientific-sessions/2025-12-03https://dompe.com/us/media/news/press-release/dompe-receives-industry-innovation-award-from-the-national-organization-for-rare-disorders-for-the-development-of-oxervatetm-eye-drops-cenegermin-bkbj-for-neurotrophic-keratitis/2025-12-03https://dompe.com/us/media/news/press-release/exscalate4cov-performed-in-italy-the-most-complex-supercomputing-experiment-to-identify-new-therapies-against-sars-cov2-virus/2025-12-03https://dompe.com/us/media/news/press-release/eu-supported-private-public-consortium-exscalate4cov-raloxifene-proposed-for-clinical-trials-after-tests-show-it-inhibits-sars-cov-2/2025-12-03https://dompe.com/us/media/news/press-release/exscalate-epidemics-exscalate-is-the-worlds-most-powerful-supercomputing-platform/2025-12-03https://dompe.com/us/media/news/press-release/ligate-new-european-backed-effort-against-pandemics-kicks-off-with-59-mln-euro/2025-12-03https://dompe.com/us/media/news/press-release/italian-researchers-abroad-and-a-startup-from-rome-win-the-first-call-for-ideas-by-dompe-the-selected-projects-concern-ophthalmology-and-the-wellness-area/2025-12-03https://dompe.com/us/media/news/press-release/3-clinical-trial-of-dompes-reparixin-for-the-treatment-of-severe-patients-with-covid-19-pneumonia/2025-12-02https://dompe.com/us/media/news/press-release/molmed-and-dompe-signed-strategic-commercialization-and-supply-agreements-for-zalmoxisr-in-europe/2025-12-03https://dompe.com/us/media/news/press-release/exscalate4cov-eus-supercomputing-and-life-science-champions-gear-up-to-fight-coronavirus-pandemic/2025-12-03https://dompe.com/us/media/news/press-release/dompe-announces-zalmoxisr-product-launch-in-germany/2025-12-03https://dompe.com/us/media/news/press-release/dompe-launches-first-biotechnological-therapy-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-in-germany/2025-12-03https://dompe.com/us/media/news/press-release/dompe-completed-investments-cycle-for-expansion-of-the-production-research-and-development-site-in-laquila/2025-12-03https://dompe.com/us/media/news/press-release/exscalate4cov-italian-medicines-agency-aifa-authorizes-raloxifene-clinical-trial-for-paucisymptomatic-covid-19-patients-treated-at-home-and-in-medical-facilities/2025-12-03https://dompe.com/us/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-ladarixin-an-oral-investigational-cxcr1-2-inhibitor-in-new-onset-type-1-diabetes-t1d/2025-12-03https://dompe.com/us/media/news/press-release/dompe-announces-results-of-phase-2-study-evaluating-the-efficacy-and-safety-of-reparixin-in-patients-with-severe-covid-19-pneumonia/2025-12-03https://dompe.com/us/media/news/press-release/dompe-and-the-farmamondo-group-exsclusive-agreement-to-distribute-oxervatetm-in-russia-and-other-cis-countries/2025-12-03https://dompe.com/us/media/news/press-release/project-neon-is-underway-in-lombardy-the-public-and-private-sector-have-come-together-to-meet-the-needs-of-those-suffering-from-diseases-of-the-nervous-system-and-tumours-with-a-high-need-for-treatment/2025-12-03https://dompe.com/us/media/news/press-release/dompe-receives-fda-approval-cenegermin-eye-drops-first-in-class-recombinant-human-nerve-growth-factor-with-potential-to-completely-heal-rare-neurotrophic-keratitis/2025-12-03https://dompe.com/us/media/news/press-release/friliverr-sport-is-an-official-partner-of-the-federazione-italiana-triathlon/2025-12-03https://dompe.com/us/media/news/press-release/european-and-south-korean-agreement-signed-on-joint-development-of-a-covid-19-treatment-using-raloxifene/2025-12-03https://dompe.com/us/media/news/press-release/dompe-substipharm-agreement-for-the-sale-of-6-brands/2025-12-03https://dompe.com/us/media/news/press-release/covid-19-brazilian-health-regulatory-agency-anvisa-authorizes-dompes-repavid-19-a-phase-2-clinical-trial-for-treatment-of-severe-patients/2025-12-03https://dompe.com/us/media/news/press-release/connectivity-specialisation-and-network-these-are-the-things-that-italians-want-from-the-pharmacy-of-the-future/2025-12-03https://dompe.com/us/media/news/press-release/dompe-further-elevates-commitment-to-ophthalmics-with-industry-leading-hires/2025-12-03https://dompe.com/us/media/news/press-release/the-galien-foundation-debuts-2019-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories/2025-12-03https://dompe.com/us/media/news/press-release/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2025-12-03https://dompe.com/us/media/news/press-release/dompe-farmaceutici-spa-announces-strategic-investment-and-collaboration-with-engitix-positioned-around-use-of-dompes-exscalate-drug-discovery-platform/2025-12-03https://dompe.com/us/media/news/press-release/leonardo-and-dompe-launch-the-first-national-digital-health-security-infrastructure-with-cloud-architecture/2025-12-03https://dompe.com/us/media/news/press-release/exscalate4cov-supercomputing-platform-wins-3-million-euro-eu-funding-to-hunt-for-new-drugs-against-coronavirus-pandemic/2025-12-03https://dompe.com/us/media/news/press-release/two-clinical-studies-to-treat-mild-to-moderate-covid-19-at-home-reveal-value-of-exscalate-dompes-ai-platform-for-drug-design/2025-12-03https://dompe.com/us/media/news/press-release/dompe-announces-activation-of-u-s-clinical-trial-sites-for-phase-3-study-of-reparixin-an-oral-investigational-cxcr1-cxcr2-inhibitor-in-hospitalized-patients-with-severe-covid-19-pneumonia/2025-12-03https://dompe.com/us/media/news/press-release/dompe-doses-first-patients-in-europe-and-us-in-phase-3-study-of-isocyclosporin-for-atopic-keratoconjunctivitis/2025-12-16https://dompe.com/us/media/news/press-release/dompe-announces-first-patient-enrolled-in-new-study-of-intranasal-ngf-in-cerebral-palsy/2026-03-30https://dompe.com/us/media/press/2026-02-06https://dompe.com/us/careers/2025-12-02https://dompe.com/us/careers/people-and-culture/2026-03-10https://dompe.com/us/careers/join-us/2026-03-12https://dompe.com/us/pharmacovigilance-and-vigilance/2025-12-12https://dompe.com/us/contact/2026-02-27https://dompe.com/us/privacy-policy/2025-12-02https://dompe.com/us/terms-of-service/2025-12-02https://dompe.com/us/cookie-policy/2025-12-02https://dompe.com/us/supplier-customer-information/2025-12-02https://dompe.com/us/accessibility/2025-12-02https://dompe.com/us/quality-complaint/2025-12-12https://dompe.com/us/medical-information/2025-12-12https://dompe.com/us/personal-data-notice-pharmacovigilance/2025-12-02https://dompe.com/us/consumer-health-data-privacy-policy/2025-12-02https://dompe.com/us/privacy-notice-product-quality-complaints/2025-12-02https://dompe.com/us/individual-rights-request-form/2025-12-02https://dompe.com/us/404/2025-12-02https://dompe.com/us/search/2025-12-02https://dompe.com/us/whistleblowing/2025-12-02